TY  - JOUR
AU  - Serra, J.M.
AU  - Uhlenbruck, S.
AU  - Meulenberg, W. A.
AU  - Buchkremer, H. P.
AU  - Stöver, D.
TI  - Nano-structuring in Solid Oxide Fuel Cells
JO  - Topics in catalysis
VL  - 40
SN  - 1022-5528
CY  - Bussum
PB  - Baltzer
M1  - PreJuSER-55582
PY  - 2006
N1  - Record converted from VDB: 12.11.2012
AB  - Healthy preterm infants fed formula with long-chain n-3 fatty acids (n-3 LCFAs) from marine oil have better early visual acuity but lower plasma phosphatidylcholine (PC) arachidonic acid (AA) and growth than infants fed formula containing linolenic acid (LLA) as the sole n-3 fatty acid. This randomized, double-blind trial was designed to study the effects of a different source of n-3 LCFAs and a shorter feeding interval on visual acuity (by Teller Acuity Card) and growth of preterm infants (n = 59; 747-1275 g birth wt), some of whom required long periods of supplemental oxygen and developed bronchopulmonary dysplasia (BPD). Infants were studied at 0, 2, 4, 6, 9, and 12 mo past term. Plasma PC AA, and normalized weight, length, and head circumference were not influenced by BPD or n-3 LCFAs except that n-3 LCFA-supplemented infants weighed less at 6 (P<0.05) and 9 (P<0.01) mo and had smaller head circumferences at 9 mo (P<0.05). Compared with control infants, however, those fed n-3 LCFAs had lower weight-for-length at 2, 6, 9, and 12 mo (P<0.0003, P<0.0114, P<0.0008, and P<0.006, respectively). n-3 LCFAs improved early (2-mo) but not later acuity among infants without BPD (P<0.02). Regardless of diet, infants with BPD had poorer grating acuity at 2 (P<0.0002) and 4 (P<0.04) mo but not thereafter.
KW  - Arachidonic Acid: blood
KW  - Arachidonic Acid: metabolism
KW  - Body Height: drug effects
KW  - Body Height: physiology
KW  - Body Weight: drug effects
KW  - Body Weight: physiology
KW  - Bronchopulmonary Dysplasia: blood
KW  - Bronchopulmonary Dysplasia: epidemiology
KW  - Bronchopulmonary Dysplasia: physiopathology
KW  - Docosahexaenoic Acids: blood
KW  - Docosahexaenoic Acids: pharmacology
KW  - Double-Blind Method
KW  - Energy Intake: physiology
KW  - Fatty Acids, Omega-3: administration & dosage
KW  - Fatty Acids, Omega-3: pharmacology
KW  - Female
KW  - Food, Fortified
KW  - Humans
KW  - Incidence
KW  - Infant, Newborn
KW  - Infant, Premature: blood
KW  - Infant, Premature: growth & development
KW  - Infant, Premature: physiology
KW  - Male
KW  - Phosphatidylcholines: blood
KW  - Phosphatidylcholines: metabolism
KW  - Phosphatidylethanolamines: blood
KW  - Phosphatidylethanolamines: metabolism
KW  - Regression Analysis
KW  - Visual Acuity: drug effects
KW  - Visual Acuity: physiology
KW  - alpha-Linolenic Acid: blood
KW  - alpha-Linolenic Acid: pharmacology
KW  - Fatty Acids, Omega-3 (NLM Chemicals)
KW  - Phosphatidylcholines (NLM Chemicals)
KW  - Phosphatidylethanolamines (NLM Chemicals)
KW  - Docosahexaenoic Acids (NLM Chemicals)
KW  - alpha-Linolenic Acid (NLM Chemicals)
KW  - Arachidonic Acid (NLM Chemicals)
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
C6  - pmid:8615350
UR  - <Go to ISI:>//WOS:000242689200013
DO  - DOI:10.1007/s11244-006-0114-6
UR  - https://juser.fz-juelich.de/record/55582
ER  -